Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 3Adenocarcinoma 3Neoplasms 2Gastric Cancer Adenocarcinoma Metastatic 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 16Radiotherapy 15Drug Therapy 14Paclitaxel 13Cisplatin 12Carboplatin 10Immunotherapy 9Esophagectomy 9Radiation 8Fluorouracil 8Surgical Procedures, Operative 7Capecitabine 7Blood Specimen Collection 7Oxaliplatin 6Nivolumab 6Immune Checkpoint Inhibitors 6Chemoradiotherapy 6nimotuzumab 5Trastuzumab 5130-nm albumin-bound paclitaxel 5sintilimab 4camrelizumab 4Leucovorin 4trastuzumab deruxtecan 3tislelizumab 3patritumab deruxtecan 3Surveys and Questionnaires 3Endoscopy 3Bevacizumab 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Esophageal Neoplasms × zolbetuximab × Clear all
NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Recruiting
2,130 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡